慢性返流性胃食管炎病人中有10%～20%并发Barrett食管,并有发生腺癌的倾向。虽然对其发生率有争议,但在首次作出Barrett食管的诊断时,已有8%～16%发生癌,而且通常已属晚期,因此2年生存率很低。为了早期发现癌变,需要定期做内镜检查和活检,发现重度异型增生时须密切随访检查,但对低度异型增生的病理诊断,目前尚缺乏组织学标准。作者等设想,发生于Barrett食管的新生物有染色体组和增殖异常的特征;用流式细胞计,不仅能在发生高度异型增生或腺癌时,而且当异型增生在组织学上辨认困难或无法辨认时,也能测出。作者等对采自64名Barrett食管和3名Barrett食管腺癌病人的317个活检标本,同时做流式细胞计数 10% to 20% of patients with chronic reflux esophagitis are complicated with Barrett’s esophagus and have a tendency to develop adenocarcinoma. Although there is controversy over its incidence, 8% to 16% of cancers have been diagnosed during the first diagnosis of Barrett’s esophagus, and are usually advanced, so the 2-year survival rate is very low. In order to detect cancerously early, endoscopy and biopsy should be performed regularly. When severe dysplasia is found, close follow-up examination is required. However, the pathological diagnosis of low-grade dysplasia currently lacks histological criteria. The authors assumed that the new organisms that occur in the Barrett’s esophagus are characterized by genomic and proliferative abnormalities; by flow cytometry, not only in the case of high-grade dysplasia or adenocarcinoma, but also when the dysplasia is histologically difficult or impossible to identify. When it is identified, it can also be measured. The author et al. also performed flow cytometry on 317 biopsy specimens from 64 Barrett’s esophagus and 3 Barrett’s esophageal adenocarcinoma patients.